Skeletal metastasis of prostate adenocarcinoma in rats: Morphometric analysis and role of parathyroid hormone-related protein

Prostate

Volumn 39, Issue 3, 1999, Pages 187-197

  Blomme, Eric A G ^a   Dougherty, Kristiann M ^b   Pienta, Kenneth J ^b   Capen, Charles C ^a   Rosol, Thomas J ^a   McCauley, Laurie K ^b  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

MATLyLu cell line; Metastasis; Osteoblast; Prostate cancer; PTHrP

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; PARATHYROID HORMONE RELATED PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE METASTASIS; BONE RADIOGRAPHY; CONTROLLED STUDY; IMMUNORADIOMETRIC ASSAY; MALE; NONHUMAN; NORTHERN BLOTTING; OSSIFICATION; OSTEOLYSIS; PATHOGENESIS; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROTEIN EXPRESSION; RAT; TUMOR GROWTH;

ADENOCARCINOMA; ALKALINE PHOSPHATASE; ANIMALS; BONE NEOPLASMS; CALCIUM; CELL DIVISION; DISEASE MODELS, ANIMAL; INCIDENCE; ISOENZYMES; MALE; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; PARATHYROID HORMONE-RELATED PROTEIN; PROSTATIC NEOPLASMS; PROTEIN BIOSYNTHESIS; PROTEINS; RATS; RNA, MESSENGER; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0033134951     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(19990515)39:3<187::AID-PROS7>3.0.CO;2-3     Document Type: Article

References (58)

1. Pienta KJ, Esper PS. Risk factors for prostate cancer. Ann Intern Med 1993;119:793-803.
2. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1996. CA Cancer J Clin 1996;65:5-27.
3. Koutsilieris M. Osteoblastic metastasis in advanced prostate cancer. Anticancer Res 1993;13:443-450.
4. Jacobs SC. Spread of prostatic cancer to bone. Urology 1983;21: 337-344.
5. Charhon SA, Chapuy MC, Delvin EE, Valentin-Opran A, Edouard CM, Meunier PJ. Histomorphometric analysis of sclerotic bone metastases from prostatic carcinoma with special reference to osteomalacia. Cancer 1983;51:918-924.
6. Goltzman D. Mechanisms of the development of osteoblastic metastases. Cancer 1997;80:1581-1587.
7. Hoffmann WE, Everds N, Pignatello M, Solter PF. Automated and semiautomated analysis of rat alkaline phosphatase isoenzymes. Toxicol Pathol 1994;22:633-638.
8. Koutsilieris M, Rabbani SA, Goltzman D. Effects of human prostatic mitogens on rat bone cells and fibroblasts. J Endocrinol 1987;115:447-454.
9. Simpson E, Harrod J, Eilon G, Jacobs JW, Mundy GR. Identification of a messenger ribonucleic acid fraction in human prostatic cancer cells coding for a novel osteoblast-stimulating factor. Endocrinology 1985;117:1615-1620.
10. Koutsilieris M, Rabbani SA, Bennett HPJ, Goltzman D. Characteristics of prostate-derived growth factors for cells of the osteoblast phenotype. J Clin Invest 1987;80:941-946.
11. Koutsilieris M, Frenette G, Lazure C, Lehoux J, Govindan MV, Polychronakos C. Urokinase-type plasminogen activator: a paracrine factor regulating the bioavailability of IGFs in PA-III cell-induced osteoblastic metastases. Anticancer Res 1993;13: 481-486.
12. Goltzman D, Bolivar I, Moroz LA, Rabbani SA. Urokinase and the mechanism of osteoblastic metastases by prostate cancer. Fibrinolysis 1992;6:63-69.
13. Achbarou A, Kaiser S, Tremblay G, Ste-Marie L, Brodt P, Goltzman D, Rabbani SA. Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo. Cancer Res 1994;54:2372-2377.
14. Rabbani SA, Desjardins J, Bell AW, Banville D, Mazar A, Henkin J, Goltzman D. An amino-terminal fragment of urokinase isolated from a prostate cancer cell line (PC-3) is mitogenic for osteoblast-like cells. Biochem Biophys Res Commun 1990;173: 1058-1064.
15. Gröne A, Werkmeister JR, Steinmeyer CL, Capen CC, Rosol TJ. Parathyroid hormone-related protein in normal and neoplastic canine tissues: immunohistochemical localization and biochemical extraction. Vet Pathol 1994;31:308-315.
16. Rosol TJ, Capen CC. Mechanisms of cancer-induced hypercalcemia. Lab Invest 1992;67:680-702.
17. Powell GJ, Southby J, Danks JA, Stillwell RG, Hayman JA, Henderson MA, Bennet RC, Martin TJ. Localization of parathyroid hormone-related protein in breast cancer metastasis: increased incidence in bone compared with other sites. Cancer Res 1991; 51:3059-3061.
18. Southby J, Kissin MW, Danks JA, Hayman JA, Moseley JM, Henderson MA, Bennet RC, Martin TJ. Immunohistochemical localization of parathyroid hormone-related protein in breast cancer. Cancer Res 1990;50:7710-7716.
19. Bundred NJ, Ratcliffe WA, Walker RA, Coley S, Morrison JM, Ratcliffe JG. Parathyroid hormone-related protein and hypercakaemia in breast cancer. Br Med J [Clin Res] 1991;303:1506-1509.
20. Bundred NJ, Walker RA, Ratcliffe WA, Warwick J, Morrison JM, Ratcliffe JG. Parathyroid hormone-related protein and skeletal morbidity in breast cancer. Eur J Cancer 1992;28:690-692.
21. Vargas SJ, Gillespie MT, Powell GJ, Southby J, Danks JA, Moseley JM, Martin TJ, Localization of parathyroid hormone-related protein mRNA expression in breast cancer and metastatic lesions by in situ hybridization. J Bone Miner Res 1992;7:971-979.
22. Kanis JA. Bone and cancer: pathophysiology and treatment of metastases. Bone 1995;17:101-105.
23. Philbrick WM, Wysolmerski JJ, Galbraith S, Holt E, Orloff J, Yang KH, Vasavada RC, Weir EC, Broadus AE, Stewart AF. Defining the roles of parathyroid hormone-related protein in normal physiology. Physiol Rev 1996;76:127-173.
24. Peehl DM, Edgar MG, Cramer SD, Deftos LJ. Parathyroid hormone-related protein is not an autocrine growth factor for normal prostatic epithelial cells. Prostate 1997;31:47-52.
25. Cramer SD, Peehl DM, Edgar MG, Wong ST, Deftos LJ, Feldman D. Parathyroid hormone-related protein (PTHrP) is an epidermal growth factor-regulated secretory product of human prostatic epithelial cells. Prostate 1996;29:20-29.
26. Blomme EAG, Sugimoto Y, McCauley LK, Lin YC, Capen CC, Rosol TJ. Stromal and epithelial cells of the canine prostate express parathyroid hormone-related protein, but not the PTH/ PTHrP receptor. Prostate 1998;36:110-120.
27. Iwamura M, Abrahamsson P, Schoen S, Cockett ATK, Deftos LJ. Immunoreactive parathyroid hormone-related protein is present in human seminal plasma and is of prostate origin. J Androl 1994;15:410-414.
28. Iwamura M, Abrahamsson P, Foss KA, Wu G, Cockett ATK, Deftos LJ. Parathyroid hormone-related protein: a potential autocrine growth regulator in human prostate cancer cell lines. Urology 1994;43:675-679.
29. Iwamura M, di Sant'Agnese PA, Wu G, Benning CM, Cockett ATK, Deftos LJ, Abrahamsson P. Immunohistochemical localization of parathyroid hormone-related protein in human prostate cancer. Cancer Res 1993;53:1724-1726.
30. Asadi F, Farraj M, Sharifi R, Malakouti S, Antar S, Kukreja S. Enhanced expression of parathyroid hormone-related protein in prostate cancer as compared with benign prostatic hyperplasia. Hum Pathol 1996;27:1319-1323.
31. Dunning WF. Prostatic cancer in the rat. Monogr Natl Cancer Inst 1963;12:351-369.
32. Isaacs JT, Heston WD, Weissman RM, Coffey DS. Animal models of the hormone-sensitive and -insensitive prostatic adenocarcinomas, Dunning R-3327-H, R-3327-HI, and R-3327-AT. Cancer Res 1978;38:4353-4359.
33. Isaacs JT, Yu GW, Coffey DS. The characterization of a newly identified, highly metastatic variant of the Dunning R-3327 rat prostate adenocarcinoma system: the MAT LyLu tumor. Invest Urol 1981;19:20-23.
34. Haq M, Goltzman D, Tremblay G, Brodt P. Rat prostate adenocarcinoma cells disseminate to bone and adhere preferentially to bone marrow derived-endothelial cells. Cancer Res 1992;52: 4613-1619.
35. Geldof AA, Rao BR. Prostatic tumor (R3327) skeletal metastasis. Prostate 1990;16:279-290.
36. Geldof AA. Models for cancer skeletal metastasis: a reappraisal of Batson's plexus. Anticancer Res 1997;17:1535-1540.
37. Henderson JE, Amizuka N, Warshawsky H, Biasotto D, Lanske BM, Goltzman D, Karaplis AC. Nucleolar localization of parathyroid hormone-related peptide enhances survival of chondrocytes under conditions that promote apoptotic cell death. Mol Cell Biol 1995;15:4064-4075.
38. McCauley LK, Beecher CA, Melton ME, Werkmeister JR, Jueppner H, Abou-Samra AB, Segre GV, Rosol TJ. Transforming growth factor β regulates steady state PTH/PTHrP receptor mRNA levels and PTHrP binding in ROS 17/2.8 osteosarcoma cells. Mol Cell Endocrinol 1994;101:331-336.
39. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidine thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-160.
40. McCauley LK, Koh AJ, Beecher CA, Cui Y, Decker JD, Franceschi RT. Effects of differentiation and transforming growth factor β1 on PTH/PTHrP receptor mRNA levels in MC3T3-E1 cells. J Bone Miner Res 1995;10:1243-1255.
41. Teter KP, Holloway DC, Sandusky GE. Assessment of PCNA (19A2) and Ki-67 (MIB1) cell proliferation markers in formalin fixed tissues. J Histotechnol 1995;18:99-104.
42. Hansen MB, Nielsen SE, Berg K. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J Immunol Methods 1989;119:203-210.
43. McCauley LK, Rosol TJ, Capen CC. Effects of cyclosporin A on rat osteoblasts (ROS 17/2.8 cells) in vitro. Calcif Tissue Int 1992; 51:291-297.
44. Mundy GR. Mechanisms of bone metastasis. Cancer 1997;80: 1546-1556.
45. Arguello F, Baggs RB, Frantz CN. A murine model of experimental metastasis to bone and bone marrow. Cancer Res 1988; 48:6876-6881.
46. Wolff JM, Ittel TH, Boeckmann W, Habib FK, Jakse G. Metastatic workup of patients with prostate cancer employing skeletal alkaline phosphatase. Anticancer Res 1997;17:2995-2998.
47. Koizumi M, Maeda H, Yoshimura K, Yamauchi T, Kawai T, Ogata E. Dissociation of bone formation markers in bone metastasis of prostate cancer. Br J Cancer 1997;75:1601-1604.
48. Cooper EH, Whelan P, Purves D. Bone alkaline phosphatase and prostate specific antigen in the monitoring of prostate cancer. Prostate 1994;25:236-242.
49. McCormack RT, Rittenhouse HG, Finlay JA, Sokoloff RL, Wang TJ, Wolfert RL, Lilja H, Oesterling JE. Molecular forms of prostate-specific antigen and the human kallikrein gene family: a new era. Urology 1995;45:729-744.
50. Gao X, Porter AT, Grignon DJ, Pontes JE, Honn KV. Diagnostic and prognostic markers for human prostate cancer. Prostate 1997;31:264-281.
51. Iwamura M, Hellman J, Cockett AT, Lilja H, Gershagen S. Alteration of the hormone bioactivity of parathyroid hormone-related protein (PTHrP) as a result of limited proteolysis by prostate-specific antigen. Urology 1996;48:317-325.
52. Cramer SD, Chen Z, Peehl DM. Prostate specific antigen cleaves parathyroid hormone-related protein in the PTH-like domain: inactivation of PTHrP-stimulated cAMP accumulation in mouse osteoblasts. J Urol 1996;156:526-531.
53. Rihani-Basharat S, Lewinson D. PTHrP(107-111) inhibits in vivo resorption that was stimulated by PTHrP(1-34) when applied intermittently to neonatal mice. Calcif Tissue Int 1997;61:426-428.
54. Cornish J, Callon KE, Nicholson GC, Reid IR. Parathyroid hormone-related peptide(107-139) inhibits bone resorption in vivo. Endocrinology 1997;138:1299-1304.
55. Leav I, Ling GV. Adenocarcinoma of the canine prostate. Cancer 1968;22:1329-1345.
56. Guise TA, Yin JJ, Taylor SD, Kumagai Y, Dallas M, Boyce BF, Yoneda T, Mundy GR. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest 1996;98:1544-1549.
57. Wysolmerski JJ, Vasavada R, Foley J, Weir EC, Burtis WJ, Kukreja SC, Guise TA, Broadus AE, Philbrick WM. Transactivation of the PTHrP gene in squamous carcinomas predicts the occurrence of hypercalcemia in athymic mice. Cancer Res 1996; 56:1043-1049.
58. Guise TA. Parathyroid hormone-related protein and bone metastases. Cancer 1997;80:1572-1580.